This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Trius Hires Chief Commercial Officer

SAN DIEGO, Jan. 10, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that J. Craig Thompson has been appointed to the newly created role of Chief Commercial Officer. With more than 18 years of pharmaceutical marketing and sales experience, Craig will initially be responsible for developing the commercial strategy, positioning and planning for the potential launch of torezolid phosphate, an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections.

Before joining Trius, Craig was Vice President of Marketing for Pfizer's Specialty Care Business Unit where he was directly responsible for the U.S. commercial strategy for products with over $1.5 billion in annual U.S. sales including the first generation oxazolidinone Zyvox ®, the anti-infectives Tygacil ®, Vfend ® and Eraxis ® as well as Rapammune ® and Relistor ®.  Prior to his 7 years at Pfizer, Craig served in positions of increasing responsibility during his 12 years at Merck where he most notably worked on the commercial planning and marketing activities for the company's anti-infectives Primaxin ®, Mefoxin ® and Cancidas ® as well as on major cardiovascular brands including Vytorin ®, Zetia ® and Zocor ®.

"Craig is a key addition to our management team and we believe that his strong infectious disease background combined with his experience in launching industry blockbusters will provide Trius with valuable commercial leadership," stated Dr. Jeffrey Stein, President and CEO of Trius Therapeutics. "His success in infectious diseases is especially relevant to his newly created role at Trius. Craig launched and led Primaxin to a position of growth, led the recent re-launch of Zyvox and effectively managed the co-positioning of Zyvox and Tygacil following the Pfizer/Wyeth merger."

"Trius provides a unique opportunity to launch torezolid phosphate, a best-in-class oxazolidinone, and to contribute to the development of its preclinical portfolio," stated Craig Thompson. "I look forward to joining this exciting company, leading the commercialization of torezolid phosphate into a successful anti-infective drug and creating value for our customers and shareholders."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs